Fluorine-18 prostate-specific membrane antigen (PSMA)-1007 PET/CT was superior to multiparametric MRI for primary locoregional staging of prostate cancer, according to results from a phase II ...

LOS ANGELES (KABC) -- New technology that's allowing doctors to pinpoint prostate cancer long before it becomes a threat is now widely available. A former firefighter mentioned how this new imaging ...

Advanced imaging, particularly PSMA PET scans, enhances detection of microscopic disease, allowing for more precise treatment ...

Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...

Figure 1. A 74-y-old man at initial staging with PSMA PET that demonstrates low uptake in primary tumor (A, arrowhead) and left pelvic side wall node (A, arrow). Bone scan was read as positive by 2 of ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

PSMA PET scans significantly enhance detection and staging of prostate cancer, improving patient stratification and survival outcomes. Three FDA-approved PSMA PET scans are available, aiding in both ...

MILAN — When added to prostate biopsy, gallium-68 prostate-specific membrane antigen (PSMA)-PET/CT improves detection of clinically significant prostate tumors and helps guide treatment planning, new ...

Pretreatment 18F-PSMA-1007 PSMA PET/CT more accurately identifies prostate tumors compared with mpMRI. Fluorine-18 prostate-specific membrane antigen-1007 positron emission tomography/computed ...

PSMA-PET molecular imaging more often triggers changes in salvage radiation treatment compared with usual care. Prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging ...